[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100411941":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":45,"collaborators":7,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":7,"enrollmentInfo":57,"targetDuration":7,"studyType":60,"phases":7,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":29,"whyStopped":7,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration","A. Electrocardiographic (ECG) leads will be place in the patient for electrocardiogram (ECG) recordings.\n\nB. Echocardiography (ECHO) will be performed by an expert member of the Neonatal Echocardiography team C. Heart Rate Variability (HRV): ECG recordings D. Growth trajectory: body weight, length, head circumference, length\u002Fweight ratio at 1-, 2-weeks prior treatment, 1-, 2-, 3-, 4-,6-,8-weeks after treatment, at 36-week PMA.",[13],{"name":14,"affiliation":15,"role":16},"Gabriel Altit, MD","Montreal Children's hospital, MUHC","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Gabriel Altit","CONTACT","5144124453","gabriel.altit@mcgill.ca",{"name":24,"role":20,"phone":21,"phoneExt":7,"email":25},"Jessica Simoneau","jessica.simoneau@muhc.mcgill.ca",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Montreal Children's hospital, Mcgill University Health Centre","RECRUITING","Montreal","Quebec","H4A 3J1","Canada","CA",{"type":36,"coordinates":37},"Point",[38,39],-73.58781,45.50884,{"lat":39,"lon":38},[42],{"name":14,"role":20,"phone":43,"phoneExt":7,"email":44},"514-412-4452","gabriel.altit@mail.mcgill.ca",{"type":16,"investigatorFullName":19,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Neonatologist","100411941","postnatal-steroids-effects-on-cardiac-function-in-extremely-preterm-100411941",false,"NCT04644094","Postnatal Steroids Effects on Cardiac Function in Extremely Preterm","\"Surveillance of Postnatal Steroids Effects on Cardiac Function in Extremely Preterm Infants With Evolving BPD: the SPEC Study.\"","SPEC","Inclusion Criteria:\n\n* \\\u003C 29 weeks of gestational age at birth admitted at the McGill University Children Hospital's neonatal intensive care unit\n* To be initiated on dexamethasone therapy for treatment of significant lung disease as per medical team decision.\n\nExclusion Criteria:\n\n* Congenital heart disease (except: Atrial septum defect (ASD), Ventricular septum defect (VSD)\n* Major congenital anomalies\u002Fgenetic disorder (Trisomy 13, 18, 21)\n* Congenital severe lung or airway malformation (Trachea-esophageal fistula, congenital pulmonary airway malformation, congenital diaphragmatic hernia)\n* Twin-twin transfusion syndrome","ALL","1 Minute",{"count":58,"type":59},21,"ESTIMATED","OBSERVATIONAL","Hypothesis\u002FStudy question\n\nIn infants born at less than 29 weeks of estimated gestational age, what are the effects of dexamethasone use on cardiac structure\u002Fperformance and lung water content?\n\nStudy objectives\n\nTo measure effects before and after dexamethasone administration on cardiac structure\u002Fperformance will be evaluated by using the M-mode technique (Devereux method (25-27) and lung water content will be specifically determined by the degree of water retention in premature lungs assessed by lung ultrasound at the pre specified time points.\n\nMethodology \u002F Study design\n\nSingle center, prospective observational cohort study planning to enroll eligible patients over a period of 12 months",[63],"Left Ventricular Hypertrophy",[65,66,67,68,69,70],"Lung ultrasound","Echocardiography","Heart rate variability","Left ventricular hypertrophy","Ductus arteriosus","Dexamethasone","2025-06-12",{"date":73,"type":74},"2025-06-17","ACTUAL",{"date":76,"type":74},"2021-06-15",{"date":78,"type":59},"2026-06",{"name":5,"class":6},1]